BHV-5000

BHV-5000 is an **orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist**, being developed primarily for neurological and neuropsychiatric disorders. Its active metabolite is **lanicemine**. Distinct from other NMDA antagonists such as ketamine, BHV-5000 is not associated with significant psychotomimetic effects, making it potentially advantageous for clinical use. The compound was originally licensed by AstraZeneca to Biohaven Pharmaceuticals. It has received orphan drug status for **Rett syndrome**, especially targeting symptoms such as breathing irregularities. Other investigated indications have included neuropathic pain and treatment-resistant depression. BHV-5000 represents an advancement in the pharmacologic modulation of glutamate via NMDA receptors, and is one of the lead candidates in Biohaven’s glutamate modulation platform[1][2][4][7].

Other names

(S)-1-(L-valyl)-N-((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate